Table 2.

Incidence of specific glomerular diseases among Olmsted County, Minnesota, residents in 1974 to 2003, by time perioda

GN Subtype1974 to 19831984 to 19931994 to 2003All Years
nRateb(95% CI)nRateb(95% CI)nRateb(95% CI)nRateb(95% CI)
IgAN70.7 (0.2 to 1.2)90.9 (0.3 to 1.5)262.1 (1.3 to 3.0)421.4 (1.0 to 1.8)
FSGS10.1 (0.0 to 0.4)111.1 (0.4 to 1.7)211.8 (1.0 to 2.6)331.1 (0.7 to 1.5)
MN30.4 (0.0 to 0.8)60.7 (0.1 to 1.3)111.0 (0.4 to 1.5)200.7 (0.4 to 1.0)
MC30.4 (0.0 to 0.8)30.3 (0.0 to 0.6)20.2 (0.0 to 0.4)80.3 (0.1 to 0.5)
MPGN10.1 (0.0 to 0.3)60.6 (0.1 to 1.0)60.5 (0.1 to 0.9)130.4 (0.2 to 0.7)
Lupus nephritis101.0 (0.4 to 1.6)70.7 (0.2 to 1.2)80.7 (0.2 to 1.1)250.8 (0.5 to 1.1)
Necrotizing GN20.3 (0.0 to 0.7)20.3 (0.0 to 0.6)80.7 (0.2 to 1.2)120.4. (0.2 to 0.7)
Crescentic GN50.7 (0.1 to 1.3)30.4 (0.0 to 0.9)20.2 (0.0 to 0.4)100.4 (0.1 to 0.6)
Other secondaryc30.3 (0.0 to 0.7)90.9 (0.3 to 1.6)201.8 (1.0 to 2.6)321.1 (0.7 to 1.5)
All GN353.9 (2.6 to 5.3)565.8 (4.3 to 7.4)1049.0 (7.3 to 10.7)1956.6 (5.7 to 7.6)
  • a CI, confidence interval; FSGS, focal segmental glomerulosclerosis; GN, glomerulonephritis; IgAN, IgA nephropathy; MC, minimal change; MN, membranous nephropathy; MPGN, membranoproliferative GN.

  • b Incidence/100,000 person-years directly age-adjusted to structure of total US population in 2000.

  • c Other secondary includes postinfection (n = 7), amyloidosis (n = 5), end-stage (n = 6) and cancer-related immune complex GN (n = 1) and MN (n = 1), HIV nephropathy (n = 1), cryoglobinemia (n = 1), and insufficient tissue for diagnosis (n = 10).